Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Starting soon · Phase 2

Conditions studied: Prostate Adenocarcinoma, Prostate Cancer

In brief

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

Key facts

Study ID

NCT07568756

Run by

University of California, Irvine

People needed

60

Starts

2026-05-01

Expected to finish

2029-05-01

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or greater at time of consent
• Prostate adenocarcinoma (no other histologic subtypes allowed)
• Prostate Cancer planned to be treated by focal therapy (e.g. cryotherapy, HIFU, or NanoKnife)
• Multiparametric-MRI imaging planned
• Planned pre- and post- treatment MRI-fusion biopsy

You may not qualify if…

• Prior treatment for any prostate malignancy (e.g. radiation, focal therapy, or systemic therapy)
• Genomic classifiers (e.g. Decipher) signifying intermediate or high-risk disease
• PSA >10
• High-risk prostate cancer (diagnosed by biopsy)
• Bilateral prostatic lobe disease

Where it is running

• Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.